Introduction
The 2010 Annual Meeting of the American Society of Clinical Oncology brought together over 30,000 clinicians and healthcare professionals in Chicago, Illinois June 4-8. Advances in the treatment and management of ovarian cancer discussed included expanded use of novel therapeutics, innovative risk assessment modalities and predictive markers, and new treatment agents and regimens.
Featured Content
• Plenary Proceedings
• Risk Assessment and Therapeutic Prediction
• Front-Line Therapy
• Recurrent Disease
• Novel Biologics
• Novel Cytotoxics
• Maintenance Therapy
Editors
Robert L. Coleman, MD bio | Judith K. Wolf, MD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours |
Release date: July 7, 2010 | Expiration date: July 6, 2011
Target Audience
The intended audience for this initiative includes gynecologic oncologists, medical oncologists, surgical oncologists, and oncology specialty pharmacists caring for patients with ovarian cancer.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Recognize biologic pathways of significance in ovarian cancer pathogenesis and resistance
- Examine current treatment options in the management of ovarian cancer
- Propose an appropriate regimen for patients with either newly diagnosed or relapsed and recurrent ovarian cancer
- Discuss toxicity prevention, identification, and management strategies for patients receiving therapy for ovarian cancer
|
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
 |
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UAN 0199-0000-10-040-H01-P). |
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 7, 2010 through July 6, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net. |
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
ACKNOWLEDGEMENT
The editors wish to thank Maureen Haas, PharmD, BCPS, BCOP, an employee of ECG, and Java Solis, a paid medical writer, for assistance in writing this document.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech BioOncology.
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Robert L. Coleman, MD
Consultant Fees
Abbott Laboratories, Allos Therapeutics, Inc., BiPar Sciences, Inc., GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc.,
Pfizer Inc, sanofi-aventis
Grants/Research Support
Abraxis BioScience, Morphotek Inc., Novartis, sanofi-aventis
Other Financial or Material Support
Abraxis BioScience, Amgen Inc., Centocor Ortho Biotech Inc.,
Daiichi Sankyo Co., Ltd., Genentech, Inc., Merck & Co., Inc., Nektar
Speakers’ Bureau
Centocor Ortho Biotech Inc., Lilly USA, LLC
Judith K. Wolf, MD
No financial relationships to disclose
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net
|
